LncRNA KCNQ1OT1 regulates the invasion and migration of hepatocellular carcinoma by acting on S1PR1 through miR-149.
Journal
Cancer gene therapy
ISSN: 1476-5500
Titre abrégé: Cancer Gene Ther
Pays: England
ID NLM: 9432230
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
01
04
2020
accepted:
22
07
2020
revised:
07
07
2020
pubmed:
6
8
2020
medline:
23
2
2022
entrez:
6
8
2020
Statut:
ppublish
Résumé
The aim of this study was to investigate the effect of lncRNA KCNQ1OT1 on HCC and to explore the possible underlying mechanisms. The expression levels of KCNQ1OT1, miR-149 and S1PR1 were detected by qRT-PCR assay. A dual luciferase reporter assay was used to detect the interaction between KCNQ1OT1 and miR-149, as well as miR-149 and S1PR1. The interaction between KCNQ1OT1 and miR-149 was further investigated by RNA pull-down assay. Wound healing assays and Transwell assays were carried out to determine cell migration and invasion. A xenograft tumour assay was used to validate the role of KCNQ1OT1 in vivo. KCNQ1OT1 and S1PR1 were significantly increased, but miR-149 was decreased in HCC cells. Luciferase reporter assays and RNA pull-down assays revealed that KCNQ1OT1 directly targeted miR-149. In addition, miR-149 bound to the 3'-UTR of S1PR1. Knockdown of KCNQ1OT1 or overexpression of miR-149 inhibited the invasion and migration of HCC cells. However, suppression of miR-149 could abrogate the effect of KCNQ1OT1 knockdown on the invasion and migration abilities of HCC cells. In vivo assays showed that KCNQ1OT1 knockdown suppressed tumour growth. This work suggests that lncRNA KCNQ1OT1 might act as a potential therapeutic target in HCC.
Identifiants
pubmed: 32753631
doi: 10.1038/s41417-020-0203-x
pii: 10.1038/s41417-020-0203-x
pmc: PMC8370874
doi:
Substances chimiques
MIRN149 microRNA, mouse
0
MicroRNAs
0
RNA, Long Noncoding
0
S1pr1 protein, mouse
0
Sphingosine-1-Phosphate Receptors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
850-863Informations de copyright
© 2020. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Toro A, Ardiri A, Mannino M, Arcerito MC, Mannino G, Palermo F, et al. Effect of pre- and post-treatment α-fetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study. BMC Surg. 2014;14:40.
doi: 10.1186/1471-2482-14-40
Clark MB, Mattick JS. Long noncoding RNAs in cell biology. Semin Cell Dev Biol. 2011;22:366–76.
doi: 10.1016/j.semcdb.2011.01.001
He Y, Meng XM, Huang C, Wu BM, Zhang L, Lv XW, et al. Long noncoding RNAs: novel insights into hepatocelluar carcinoma. Cancer Lett. 2014;344:20–7.
doi: 10.1016/j.canlet.2013.10.021
Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 2011;21:354–61.
doi: 10.1016/j.tcb.2011.04.001
Moran VA, Perera RJ, Khalil AM. Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs. Nucleic Acids Res. 2012;40:6391–400.
doi: 10.1093/nar/gks296
Zhu B, Cheng XB, Jiang YL, Cheng M, Chen LP, Bao JJ, et al. Silencing of KCNQ1OT1 decreases oxidative stress and pyroptosis of renal tubular epithelial cells. Diabetes Metab Syndr Obes. 2020;13:365–75.
doi: 10.2147/DMSO.S225791
Ren Y, Gao XP, Liang H, Zhang H, Hu CY. LncRNA KCNQ1OT1 contributes to oxygen-glucose-deprivation/reoxygenation-induced injury via sponging miR-9 in cultured neurons to regulate MMP8. Exp Mol Pathol. 2020;112:10435.
doi: 10.1016/j.yexmp.2019.104356
Zhang S, Ma H, Zhang D, Xie S, Wang W, Li Q, et al. LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling. Cell Death Dis. 2018;9:742.
doi: 10.1038/s41419-018-0793-5
Li C, Miao R, Zhang J, Qu K, Liu C. Long non-coding RNA KCNQ1OT1 mediates the growth of hepatocellular carcinoma by functioning as a competing endogenous RNA of miR-504. Int J Oncol. 2018;52:1603–12.
pubmed: 29532864
Zhang Y, Guo X, Xiong L, Yu L, Li Z, Guo Q, et al. Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting Akt-mTOR pathway. Mol Cancer. 2014;13:253.
doi: 10.1186/1476-4598-13-253
Liu XX, Wang M, Xu D, Yang JH, Kang HF, Wang XJ, et al. Quantitative assessment of the association between genetic variants in microRNAs and colorectal cancer risk. Biomed Res Int. 2015;2015:1–10.
Izquierdo L, Ingelmo-Torres M, Mallofrã C, Lozano JJ, Verhasselt-Crinquette M, Leroy X, et al. Prognostic value of microRNA expression pattern in upper tract urothelial carcinoma. BJU Int. 2014;113:813–21.
doi: 10.1111/bju.12551
Xu Q, Liu JW, Yuan Y. Comprehensive assessment of the association between miRNA polymorphisms and gastric cancer risk. Mutat Res Rev Mutat Res. 2015;763:148–60.
doi: 10.1016/j.mrrev.2014.09.004
Wang C, Mao J, Redfield S, Mo Y, Lage JM, Zhou X. Systemic distribution, subcellular localization and differential expression of sphingosine-1-phosphate receptors in benign and malignant human tissues. Exp Mol Pathol. 2014;97:259–65.
doi: 10.1016/j.yexmp.2014.07.013
Zhou P, Huang G, Zhao Y, Zhong D, Xu Z, Zeng Y, et al. MicroRNA-363-mediated downregulation of S1PR1 suppresses the proliferation of hepatocellular carcinoma cells. Cell Signal. 2014;26:1347–54.
doi: 10.1016/j.cellsig.2014.02.020
Zhang Y, Guo X, Xiong L, Kong X, Xu Y, Liu C, et al. MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett. 2012;586:4362–70.
doi: 10.1016/j.febslet.2012.10.053
Lin ZY, Huang YQ, Zhang YQ, Han ZD, He HC, Ling XH, et al. MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1. Int J Cancer. 2014;135:541–50.
doi: 10.1002/ijc.28707
Zhang Z, Zhang Y, Sun XX, Ma X, Chen ZN. MicroRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma. Mol Cancer. 2015;14:5.
doi: 10.1186/1476-4598-14-5
Jiang R, Zhao C, Wang X, Wang S, Sun X, Tian Y, et al. Resistin-like molecule-β promotes invasion and migration of gastric carcinoma cells. Med Sci Monit. 2016;22:937–42.
doi: 10.12659/MSM.895598
Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia Pacific region. J Gastroenterol Hepatol. 2010;24:346–53.
doi: 10.1111/j.1440-1746.2009.05784.x
Chi HC, Tsai CY, Tsai MM, Yeh CT, Lin KH. Roles of long noncoding RNAs in recurrence and metastasis of radiotherapy-resistant cancer stem cells. Int J Mol Sci. 2017;18:1903.
doi: 10.3390/ijms18091903
Klingenberg M, Matsuda A, Diederichs S, Patel T. Non-coding RNA in hepatocellular carcinoma: mechanisms, biomarkers and therapeutic targets. J Hepatol. 2017;67:603.
doi: 10.1016/j.jhep.2017.04.009
Bartel D. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
doi: 10.1016/S0092-8674(04)00045-5
Kwak PB, Iwasaki S, Tomari Y. The microRNA pathway and cancer. Cancer Sci. 2010;101:2309–15.
doi: 10.1111/j.1349-7006.2010.01683.x
Kirschner MB, Cheng YY, Armstrong NJ, Lin RCY, Kao SC, Linton A, et al. MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. Mol Oncol. 2015;9:715–26.
doi: 10.1016/j.molonc.2014.11.007
Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, et al. Prognostic and predictive value of a microRNA signature in stage Ii colon cancer: a microRNA expression analysis. Lancet Oncol. 2013;14:1295–306.
doi: 10.1016/S1470-2045(13)70491-1
Bagnoli M, Canevari S, Califano D, Losito S, Maio MD, Raspagliesi F, et al. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. Lancet Oncol. 2016;17:1137–46.
doi: 10.1016/S1470-2045(16)30108-5
Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008;13:48–57.
doi: 10.1016/j.ccr.2007.12.008
Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009;361:1437–47.
doi: 10.1056/NEJMoa0901282
Wong CC, Wong C, Tung EK, Au SL, Lee JM, Poon RT, et al. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology. 2011;140:322–31.
doi: 10.1053/j.gastro.2010.10.006
Yang H, Fang F, Chang R, Yang L. MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor β receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology. 2013;58:205–17.
doi: 10.1002/hep.26315
Qu J, Li M, Zhong W, Hu C. Competing endogenous RNA in cancer: a new pattern of gene expression regulation. Int J Clin Exp Med. 2015;8:17110.
pubmed: 26770304
pmcid: 4694204
Zhao N, Sun H, Sun B, Zhu D, Zhao X, Wang Y, et al. Mir-27a-3p suppresses tumor metastasis and VM by down-regulating VE-cadherin expression and inhibiting EMT: an essential role for Twist-1 in HCC. Sci Rep. 2016;6:23091.
doi: 10.1038/srep23091
Tania M, Khan MA, Fu J, Tania M, Khan MA, Fu J. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumor Biol. 2014;35:7335–42.
doi: 10.1007/s13277-014-2163-y
Battistelli C, Cicchini C, Santangelo L, Tramontano A, Grassi L, Gonzalez FJ, et al. The Snail repressor recruits EZH2 to specific genomic sites through the enrollment of the lncRNA HOTAIR in epithelial-to-mesenchymal transition. Oncogene. 2017;36:942–55.
doi: 10.1038/onc.2016.260
Tang JW, Xie Y, Xu XL, Yin Y, Jiang RQ, Deng L, et al. Bidirectional transcription of Linc00441 and RB1 via H3K27 modification-dependent way promotes hepatocellular carcinoma. Cell Death Dis. 2017;8:e2675.
doi: 10.1038/cddis.2017.81
Ando H, Okamoto A, Yokota M, Shimizu K, Asai T, Dewa T, et al. Development of a miR-92a delivery system for anti-angiogenesis-based cancer therapy. J Gene Med. 2013;15:20–7.
doi: 10.1002/jgm.2690
Shigoka M, Tsuchida A, Matsudo T, Nagakawa Y, Saito H, Suzuki Y, et al. Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int. 2010;60:351–7.
doi: 10.1111/j.1440-1827.2010.02526.x
Wang R, Yu Z, Chen F, Xu H, Shen S, Chen W, et al. Mir-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK/PI3K/AKT signaling pathway. Biomed Pharmacother. 2018;103:1632.
doi: 10.1016/j.biopha.2018.03.005